Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

@article{Bieniasz2015PreclinicalEO,
  title={Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.},
  author={Magdalena Bieniasz and Parvathi Radhakrishnan and Najme Faham and O Jean-PaulDeLa and Alana L. Welm},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 24},
  pages={5588-600}
}
PURPOSE Recent studies have demonstrated that short-form Ron (sfRon) kinase drives breast tumor progression and metastasis through robust activation of the PI3K pathway. We reasoned that upfront, concurrent inhibition of sfRon and PI3K might enhance the antitumor effects of Ron kinase inhibitor therapy while also preventing potential therapeutic resistance… CONTINUE READING